TY  - JOUR
TI  - Key actors in cancer therapy: epigenetic modifiers
AB  - Epigenetic reprogramming plays a crucial role in the tumorigenicity and maintenance of tumor-specific gene expression thatespecially occurs through DNA methylation and/or histone modifications. It has well-defined mechanisms. It is known that alterationsin the DNA methylation pattern and/or the loss of specific histone acetylation/methylation markers are related to several hallmarks ofcancer, such as drug resistance, stemness, epithelial–mesenchymal transition, and metastasis. It has also recently been highlighted thatepigenetic alterations are critical for the regulation of the stemlike properties of cancer cells (tumor-initiating cells; cancer stem cells).Cancer stem cells are thought to be responsible for the recurrence of cancer which makes the patient return to the clinic with metastatictumor tissue. Hence, the dysregulation of epigenetic machinery represents potential new therapeutic targets. Therefore, compounds withepigenetic activities have become crucial for developing new therapy regimens (e.g., antimetastatic agents) in the fight against cancer.Here, we review the epigenetic modifiers that have already been used in the clinic and/or in clinical trials, related preclinical studies incancer therapy, and the smart combination strategies that target cancer stem cells along with the other cancer cells. The emerging role ofepitranscriptome (RNA epigenetic) in cancer therapy has also been included in this review as a new avenue and potential target for thebetter management of cancer-beneficial epigenetic machinery
AU  - AZTOPAL, Nazlıhan
AU  - SELVİ, Selin
AU  - AKAR, Remzi Okan
AU  - ULUKAYA, Engin
DO  - 10.3906/biy-1903-39
PY  - 2019
JO  - Turkish Journal of Biology
VL  - 43
IS  - 3
SN  - 1300-0152
SP  - 155
EP  - 170
DB  - TRDizin
UR  - http://search/yayin/detay/336040
ER  -